Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson(Dana-Farber Cancer Institute), Julio C. Chávez(Moffitt Cancer Center), Alison R. Sehgal(UPMC Hillman Cancer Center), Basem M. William(The Ohio State University), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Gilles Salles(Université Claude Bernard Lyon 1), Pashna N. Munshi(Georgetown Lombardi Comprehensive Cancer Center), Carla Casulo(University of Rochester Medical Center), David G. Maloney(Fred Hutch Cancer Center), Sven de Vos(Los Angeles Medical Center), Ran Reshef(Columbia University Irving Medical Center), Lori A. Leslie(Hackensack University Medical Center), Ibrahim Yakoub‐Agha(Centre Hospitalier Universitaire de Lille), Olalekan O. Oluwole(Vanderbilt University Medical Center), Henry C. Fung(Fox Chase Cancer Center), Joseph D. Rosenblatt(University of Miami), John M. Rossi(Kite (United States)), Lovely Goyal(Kite (United States)), Vicki Plaks(Kite (United States)), Yin Yang(Kite (United States)), Remus Vezan(Kite (United States)), Mauro P. Avanzi(Kite (United States)), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center)
The Lancet Oncology
December 8, 2021
Cited by 608

Abstract


Related Papers

No related papers found

Powered by citation graph analysis